NEWPORT phase iii Drugs MODULE
Intelligence on products still in Phase III clinical trials
What Phase iii drugs can help you do
How you benefit
•
•
•
•
•
•
•
•
•
•
•
•
Conduct better, earlier product targeting
Monitor the competition
Seek out partners earlier
Anticipate line extensions for launched products
Predict the strategies innovators will use to
protect their franchise
In today’s hyper-competitive pharmaceutical industry,
generic companies and API manufacturers need every
advantage they can get over their rivals.
GAIN A COMPETITIVE EDGE BY TARGETING
PRODUCTS EARLIER
The Newport Phase III Drugs Module enables you to target
new development opportunities as soon as possible.
Seamlessly integrated into Newport Global™ and
Newport Premium™, Phase III Drugs extends the base
system’s coverage of APIs to include more than 400
compounds in late-stage development (Phase III
clinical, registration or under review).
It includes patent, synthesis, and clinical development
details for these late-stage compounds, equipping
you to begin your targeting and competitive tracking
processes earlier than ever before.
For pharmaceutical products that are already in the
market, Phase III Drugs adds information about further
clinical trials taking place, giving you insights into the
possible line extensions or additional indications that
are being pursued in different markets.
Two dedicated searches enable you to identify
development-stage products by exacting criteria. You
can review a launched drug’s complete development
history and receive email alerts as new drugs progress
through the development pipeline.
Phase III drugs Helps your strategic
planning team to:
•
Identify opportunities that match your strategic
needs and strengths years before launch
•
Adjust your research timing, priorities, and
resources based on competitive intelligence for
products from Phase III through pre-launch
•
Anticipate line-extensions for products in the
market and strategies for protecting franchises
Monthly intelligence updates
Simple web-based interface
Comprehensive training and technical support
Integrated on-line help
Zero cost deployment
Secure, confidential hosted access
Phase III drugs Helps your business
development team to:
•
Profile candidate products for acquisition,
alliances, licensing, or supply and manufacturing
•
Track and monitor patenting and clinical trial
activities for products of interest
•
Evaluate candidate products against the earliest
competitive intelligence
Phase III drugs Helps your product
intelligence team to:
HOW TO SUBSCRIBE
The Newport Phase III
Drugs Module is an optional
subscription module that
may be added on a per-seat
basis to Newport Premium™
(for Generics) or Newport
Global™ (for Generics)
product configurations for an
additional annual charge.
A subscription to a base
system is required before
purchasing this module. To
get a quotation, contact your
account manager or visit
science.thomsonreuters.com/
info/sales
THOMSON REUTERS
REGIONAL OFFICES
North America
Philadelphia +1 855 260 5607
+1 215 386 0100
•
View regulatory filings, such as US DMFs, for
products still in Phase III clinical trials
•
Explore chemical structure diagrams and routes
of synthesis with patent and literature references
Europe, Middle East and Africa
London
+0800 145 6412
•
Uncover additional indications being pursued for
drugs in the marketplace
Asia Pacific
Singapore
Tokyo
Phase III drugs Also aids company
and patent intelligence
The Newport Phase III Drugs Module can help your
company intelligence team to monitor development
portfolios of hundreds of companies, including
for line extensions for launched products. It can
also help your patent intelligence team to explore
worldwide patent families and individual patents for
products in Phase III clinical trials, pre-registration,
registration, and pre-launch phases.
For both launched and Phase III drugs, get a
snapshot of which additional development
programs are being pursued and what
status has been reached.
Latin America
+55 11 8370 9845
+65 6775 5088
+81 3 5218 6500
For a complete office list visit: science.thomsonreuters.com/contact
LS 201207 SPEC NP3DFS
Copyright © 2012 Thomson Reuters